Resilinc study: 32% of the S&P 500 impacted in 2017
Resilinc Publishes 2017 EventWatch® Supply Chain Disruption Annual Report
In 2017, natural disasters and weather-related events proved to be a considerable source of disruption across the globe and especially the United States, which for the first time became the most impacted region in the world. In addition to natural disasters, factory fires remain a significant risk to supply chains, and cyber-attacks increased substantially in 2017.
The annual report is a study of the prior year's supply chain disruption events: natural disasters, extreme weather, fires, environmental hazards, geopolitical occurrences, and other business developments. These events are tracked and their impact upon manufacturing supply chains assessed by the Resilinc technology and expert teams. The Resilinc EventWatch® service provides 24x7 alerting and notifications to subscribers tracking their exposure. Hundreds of millions of news alerts across over 100,000 sources in 44 languages were monitored and analyzed in 2017 alone.
"This should be a wake-up call for business leaders around the globe," states Bindiya Vakil, CEO of Resilinc. "2017 was a turbulent year for US companies and their supply chains, causing a hidden drag that must be addressed. With 32% of S&P 500 companies potentially impacted, the economic damage is enormous." Hurricanes Harvey, Irma, and Maria alone contributed to significant impacts to business in 2017, finds the report.
In 2017, Resilinc EventWatch contacted more than 19,000 unique suppliers for potential impacts, which generated responses from 53% of those suppliers contacted. "When an event occurs, action must be taken by all members of the supply chain, to ensure that appropriate steps are taken to avoid any potential impacts. The faster and more efficiently these steps are taken, the less the overall economic consequences," said Shahzaib Khan, Director of EventWatch at Resilinc.
The annual report analyzed incidents by risk type, industry, geography, disruption potential, and month for 2016 and 2017 for comparison purposes by industry and geography. The report highlights global supply chain risk trends through a variety of lenses and aids supply chain planning for 2018 and beyond.
Key report highlights include:
- The top 5 events of 2017 in terms of impact to businesses were:
- Late winter storm in the Northeast USA, March
- Weather related damage closed the US/Mexico Laredo border, May
- Hurricane Harvey in USA, August
- Hurricane Irma in USA, September
- Hurricane Maria in Puerto Rico, September
- For the first time, North America was the most disrupted region by natural disasters.
- Factory fire/explosion represented the majority of EventWatch bulletins in 2017 with 18% of bulletins notified.
- Cyber-attacks increased substantially, particularly of the ransomware variety.
- The automotive industry was the most disrupted industry as it saw an increase of 30% bulletins published. All industries observed increases of around 300 bulletins or greater in 2017.
For more information
An electronic version of the annual report is available at http://info.resilinc.com/eventwatch-2017-annual-report-0
The Resilinc EventWatch service is available at https://info.resilinc.com/eventwatch-professional-enterprise
Resilinc is the leading global supplier of supply chain risk and resiliency solutions. Industry leading companies such as IBM, General Motors, EMC, Amgen and Western Digital rely on Resilinc to plan for potential supply chain failures, and to protect revenue despite supply chain disruptions worldwide. For more information about our solutions, please visit www.resilinc.com.
Contact: Grover Righter, Chief Marketing Officer Marketing.Team@Resilinc.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resilinc via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00 | Pressemelding
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t
CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00 | Pressemelding
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos
Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00 | Pressemelding
Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00 | Pressemelding
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated
GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12 | Pressemelding
SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no
Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00 | Pressemelding
OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist